Brief: DiaMedica Therapeutics Receives Health Canada Clearance To Initiate Phase 2 Study Of Dm199 In Preeclampsia
05/03/2026 12:36
March 5 (Reuters) - DiaMedica Therapeutics Inc DMAC.O: DIAMEDICA THERAPEUTICS RECEIVES HEALTH CANADA CLEARANCE TO INITIATE PHASE 2 STUDY OF DM199 IN PREECLAMPSIA DIAMEDICA THERAPEUTICS INC - TO INITIATE PHASE 2 DM199 TRIAL IN 2026; US AND UK EXPANSION PLANNED Source text: ID:nBwbk92lHa Further company coverage: DMAC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program